Q HIGHLIGHTS (just read it cover to cover)
Cash up 720% since Dec 2017
Receivables up 100% since Dec 2017
Assets up 29%.
Accounts payable down.
Long term liabilities = 0.
Revenues started.
Gross profit 79% on revenue.
R &D costs down 2000%.
Defined as commercial stage company as of Q4 2017...not clinical anymore.
Caverstem, Amniostem, stemspine patents good til 2026-2027. Agreements in place with parent company and others on compensation to CMT for high royalties.
$400k Debenture debt paid.
Global note paid
Warbington took stock based compensation instead of pay. Plus purchased almost 10M more on his own.
Commenced marketing of Caverstem machines and kits.
Expect going forward sufficient cash for operations due to commercialization cash flows, including completing clinical trials upcoming.
Other (not in Q) highlights.
As we have seen over the last 6 weeks, additional notes were converted. While we cannot speculate as to how many, or what's left, given the amounts and form T,s, should be close to debt free from convertible notes.
The conference....need I say more...it's been debated at nauseum. Suffice to say this is likely to explode revenues in short order.
Additional pending patent applications, will secure bright future for company, giving further exclusivity for many many years.
And again, derivative value loss is offset by the value of underlying stock. It's not a loss for the company in actual money. It's a loss on what they would have earned if they had known that the stock price would have risen so much since issuance of the derivative, and it's a greater expense in the event the company wants to buy them back. It is only placed on balance sheet as a net loss due to required accounting principles.
Company is in damn good shape, not only for otc, but in general.
Catalysts galore. Weeks and months ahead are super bright.
Go celz.
